Technical Data
I7661-74
Interferon alpha, Human Sampler (IFNa1) BioAssay™ Kit
12Vials
Growth Factors, Cytokines Storage: -70°CShipping: Dry Ice
Size: 12x20KU

Interferons (IFNs) appear early after viral infection locally and systematically to limit spread of viral infection. They also affect cell differentiation, growth, surface antigen expression and immunoregulation. There are three naturally occurring interferons: alpha, beta and gamma. Interferon alpha (IFN-alpha, IFNa) is also known as leukocyte interferon. B-lymphocytes are the predominant cellular producers of INF-alpha. IFN-alpha is derived from lymphoblastic tissue. IFN-alpha comprises a family of related, homologous proteins, each exhibiting a unique activity profile. The activities of the different IFN-alpha species on viruses can vary twenty fold or more. INF-alpha has a number of therapeutic applications in the treatment of various human cancers and diseases of viral origin. Recombinant IFN-alphas from both natural and synthetic genes bind to a common cell surface receptor and induce anti-viral activity in a variety of cell lines. When binding to discrete cell surface receptors on target cells, IFN-alpha induces rapid changes in Jak/Stat phosphorylation, which intiates the Jak/Stat signaling pathway. IFN-alpha signaling also involves production of DAG without an increased intracellular free calcium concentration and the subsequent activation of calcium-independent isoforms of PKC (beta and epsilon). All IFN-alpha signaling pathways lead to final alterations of gene expression, which mediate their pleiotropic biologic activities. IFN-alpha remains the most frequently used IFN for both research and clinical applications. It was first approved for combating malignancies. Anti-viral applications such as chronic Hepatitis B and C now make up the bulk of IFN sales. Different countries throughout the world have approved Hu-IFNa for different applications include: Chronic Hepatitis B, Chronic Hepatitis C, Hairy Cell Leukemia, Kaposi's Sarcoma (AIDS-related), Cutaneous T-cell Leukemia, Chronic Myeloid Leukemia, Renal Cell Carcinoma, Non-Hodgkin's Lymphoma, Adjuvant Therapy for Malignant Melanoma, Bladder Cell Carcinoma, Colon Carcinoma, Laryngeal Papillomatosis, Cervical Dysplasia, Condylomata Acuminata (Venereal Warts), Multiple Myeloma.

By testing and selecting specific alpha interferons to meet your research needs, you may benefit from improved effectiveness and reduced the quantity of cytokine required, thereby reducing experimental costs.

Kit Components (20,Ku):
I7661-74B1 Alpha A
I7661-74B2 Alpha B2
I7661-74B3 Alpha C
I7661-74B4 Alpha D
I7661-74B5 Alpha F
I7661-74B6 Alpha G
I7661-74B7 Alpha H2
I7661-74B8 Alpha I
I7661-74B9 Alpha J1
I7661-74B10 Alpha K
I7661-74B11 Alpha 4b
I7661-74B12 Alpha WA

Storage and Stability:
Aliquot to avoid repeated freezing and thawing and freeze at -70°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquots are stable for at least 12 months.
Source: Human leukocyte mRNA expressed in E. coli
Purity: 95%
Concentration: ~2x10e5u/ml
Form: Supplied as a liquid in PBS, pH 7.2, 0.1% BSA.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Rubinstein, S., Familletti, P.C., Pestka, S., Convenient Assay for Interferons, J. Virol. 37: 755-758 (1981). 2. Familletti, P.C., Rubinstein, S., Pestka, S., A Convenient and Rapid Cytopathic Effect Inhibition Assay for Interferon, in Methods in Enzymology, Vol. 78 (S. Pestka, ed.), Academic Press, New York, 387-394 (1981). 3. Pestka, S., Interferon Standards and General Abbreviations, in Methods in Enzymology (S. Pestka, ed.), Academic Press, New York 119: 14-23 (1986

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.